Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

The Quest for Better Biomarkers of Bone Turnover in CKD

Thomas L. Nickolas
JASN May 2018, 29 (5) 1353-1355; DOI: https://doi.org/10.1681/ASN.2018030289
Thomas L. Nickolas
Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • renal osteodystrophy
  • bone turnover
  • hyperparathyroidism

Renal osteodystrophy (ROD) is a complex heterogeneous disorder of bone that results from abnormal calcium and phosphate metabolism, decreased calcitriol synthesis, increased parathyroid hormone (PTH) levels, metabolic acidosis, and defective bone mineralization. Specifically, ROD is the bone component of CKD–Mineral and Bone Disease (CKD-MBD), a disorder of bone, mineral metabolism, and soft tissue calcifications. More than one in ten Americans has CKD1 and CKD-MBD occurs in nearly 100% of patients with CKD. ROD results in bone loss2 and fractures3 and has been linked to increased risk of vascular calcifications and cardiovascular (CV) events.4 For patients with CKD, compared with the general population, fractures and CV risk are >17-5 and >1.4-fold6 greater, respectively, and mortality rates after fracture and CV events are >3-7 and >10-fold greater,6 respectively. In 2010, health care–associated costs after fracture exceeded $600 million.7 Thus, improvements in the diagnosis and clinical management of ROD are a critical first step in the long-term goal of reducing morbidity and mortality in patients with CKD-MBD.

Diagnosis of turnover is an impediment to ROD treatment. The 2005 Kidney Disease Improving Global Outcomes (KDIGO) committee shifted the historical nomenclature of ROD type (e.g., osteitis fibrosa cystica) to a unified classification system on the basis of bone Turnover, Mineralization, and Volume (TMV), and ROD turnover is now classified as low- or high-turnover ROD. Current treatment of ROD is focused on suppressing high turnover with active vitamin D (calcitriol and analogs) and/or calcimimetics, while simultaneously avoiding the development of low-turnover ROD through excessive use of these same agents. In addition, emerging data and clinical experience suggest that ROD with bone loss or fractures may be safely managed with treatments that are used for osteoporosis (antiresorptives for high-turnover ROD; anabolics for low-turnover ROD), as long as low-turnover ROD can be identified and avoided. The primary concern in identifying and preventing the development of low-turnover ROD is that it has been associated with risk of fractures8 and vascular calcifications that may increase CV risk.4 Guidelines and clinical experience recommend that diagnosis of turnover should be obtained before starting ROD treatment, and turnover should be monitored during the course of therapy because turnover may change, thus requiring an alteration to the treatment (e.g., discontinuing calcitriol or calcimimetics for over suppression of turnover). The gold standard method to define turnover is double-labeled tetracycline transiliac crest bone biopsy with quantitative histomorphometry. However, bone biopsy is invasive, expensive, requires approximately 3-months for results, cannot be used for rapid decision making, is not easily implemented as a disease and treatment monitoring tool, and is available at only several centers worldwide. In addition, it assumes that iliac crest remodeling is representative of systemic turnover. Because these limitations render bone biopsy impractical and in the vast majority of cases impossible to use for either diagnosis or treatment monitoring, KDIGO recommends that circulating levels of PTH and bone specific alkaline phosphatase (BSAP) can be used in the clinic to diagnose and guide management of ROD.

Unfortunately, PTH and other clinically used markers of bone formation and resorption provide less than optimal discrimination of turnover type in ROD. The largest bone biopsy study to date reported that the areas under the curve (AUCs) for PTH and markers of bone formation (BSAP, procollagen type-1 N-terminal propeptide [P1NP]) are between 0.70 and 0.80, and that combining PTH with BSAP or P1NP does not improve discrimination.9 Therefore, although PTH and bone turnover markers discriminate turnover type, they lack sufficient accuracy to guide completely and safely our ROD treatment decisions or to be used as part of clinical trial protocols of antifracture agents in patients with CKD. Better noninvasive biomarkers of turnover in ROD are needed to overcome these important limitations and help advance patient care and the development and study of antifracture pharmacologic agents in CKD.

In this edition of the Journal of the American Society of Nephrology, Salam et al.10 report their findings on the use of bone imaging and circulating bone turnover markers as biomarkers of turnover type. In 69 patients with CKD stages 3 through 5D, they measured gold standard bone turnover by tetracycline double-labeled transiliac crest bone biopsy, obtained measures of bone structure by dual energy x-ray absorptiometry and high-resolution peripheral quantitative computed tomography (HR-pQCT), and assayed PTH and circulating markers of bone formation (BSAP, P1NP) and resorption (C-telopeptide [CTX] and tartrate resistant acid phosphatase 5b [Trap5b]). They reported that PTH and markers of bone formation and resorption all discriminated turnover. BSAP discriminated low turnover best with an AUC of 0.824, and although PTH did not discriminate low turnover it had the best discrimination of high turnover with an AUC of 0.760. They also reported that several structural features from bone imaging correlated with and discriminated turnover, most notably that greater total volumetric bone density and greater cortical bone volume/tissue volume discriminated low from non-low turnover, with AUCs of 0.811 and 0.802, respectively. Similar to other studies, combining PTH, bone turnover markers, and bone imaging measures did not improve discrimination of turnover types.

These data confirm that the quest to find better biomarkers of turnover is far from over. The diagnostic test characteristics reported by Salam et al.10 for PTH and circulating protein biomarkers of turnover are similar and consistent with those reported in previous bone biopsy series,9 supporting the consensus that the accuracy of these biomarkers is insufficient for ROD management at large. The use of bone structural parameters to identify bone dynamic parameters is highly controversial and doubtable because the effects of bone turnover on bone structure require about 3–6 months to be detectable on HR-pQCT imaging. Furthermore, bone biopsy findings contradict the assumption that imaging of bone structure can identify bone turnover, because we have found that lower trabecular bone volume/tissue volume and decreased cortical bone volume are present in patients with adynamic or low bone turnover, likely due to past effects of high remodeling rates.

Do these data nudge forward the paradigm of ROD treatment? On the basis of the 2017 KDIGO Guidelines, PTH and BSAP can be used in the clinic to identify turnover type because markedly high or low levels identify underlying turnover.11 In cases when their levels are neither high nor low, bone biopsy is recommended if the results would affect treatment decisions (a none graded recommendation). Thus, nothing has changed. Unfortunately, almost all of our patients are affected by this complex, lethal, and often forgotten complication of CKD and one of our main impediments to developing and studying novel agents to mitigate its effects is the lack of noninvasive biomarkers that can be used for its diagnosis and treatment monitoring. Therefore, the study by Salam et al.10 provides a wake-up call to the scientific community, funding agencies, and patient advocacy and industry groups working in CKD to jump start the effort to finding better noninvasive biomarkers of ROD.

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy,” on pages 1557–1565.

  • Copyright © 2018 by the American Society of Nephrology

References

  1. ↵
    1. Coresh J,
    2. Selvin E,
    3. Stevens LA,
    4. Manzi J,
    5. Kusek JW,
    6. Eggers P, et al
    .: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007
    OpenUrlCrossRefPubMed
  2. ↵
    1. Nickolas TL,
    2. Stein EM,
    3. Dworakowski E,
    4. Nishiyama KK,
    5. Komandah-Kosseh M,
    6. Zhang CA, et al
    .: Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res 28: 1811–1820, 2013
    OpenUrlCrossRefPubMed
  3. ↵
    1. Naylor KL,
    2. McArthur E,
    3. Leslie WD,
    4. Fraser LA,
    5. Jamal SA,
    6. Cadarette SM, et al
    .: The three-year incidence of fracture in chronic kidney disease. Kidney Int 86: 810–818, 2014
    OpenUrlCrossRefPubMed
  4. ↵
    1. London GM,
    2. Marty C,
    3. Marchais SJ,
    4. Guerin AP,
    5. Metivier F,
    6. de Vernejoul MC
    : Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15: 1943–1951, 2004
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Alem AM,
    2. Sherrard DJ,
    3. Gillen DL,
    4. Weiss NS,
    5. Beresford SA,
    6. Heckbert SR, et al
    .: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58: 396–399, 2000
    OpenUrlCrossRefPubMed
  6. ↵
    1. Go AS,
    2. Chertow GM,
    3. Fan D,
    4. McCulloch CE,
    5. Hsu CY
    : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kim SM,
    2. Long J,
    3. Montez-Rath M,
    4. Leonard M,
    5. Chertow GM
    : Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res 31: 1803–1809, 2016
    OpenUrlPubMed
  8. ↵
    1. Coco M,
    2. Rush H
    : Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115–1121, 2000
    OpenUrlCrossRefPubMed
  9. ↵
    1. Sprague SM,
    2. Bellorin-Font E,
    3. Jorgetti V,
    4. Carvalho AB,
    5. Malluche HH,
    6. Ferreira A, et al
    .: Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67: 559–566, 2016
    OpenUrlCrossRefPubMed
  10. ↵
    1. Salam S,
    2. Gallagher O,
    3. Gossiel F,
    4. Paggiosi M,
    5. Khwaja A,
    6. Eastell R
    : Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. J Am Soc Nephrol 29: 1557–1565, 2018
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Ketteler M,
    2. Block GA,
    3. Evenepoel P,
    4. Fukagawa M,
    5. Herzog CA,
    6. McCann L, et al
    .: Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: What’s changed and why it matters. Kidney Int 92: 26–36, 2017
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 29 (5)
Journal of the American Society of Nephrology
Vol. 29, Issue 5
May 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
The Quest for Better Biomarkers of Bone Turnover in CKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Quest for Better Biomarkers of Bone Turnover in CKD
Thomas L. Nickolas
JASN May 2018, 29 (5) 1353-1355; DOI: 10.1681/ASN.2018030289

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The Quest for Better Biomarkers of Bone Turnover in CKD
Thomas L. Nickolas
JASN May 2018, 29 (5) 1353-1355; DOI: 10.1681/ASN.2018030289
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Molecular Characterization of Membranous Nephropathy: Quo Vadis?
  • More than a Marker: Arginase-1 in Kidney Repair
  • Enabling Patient Choice: The “Deciding Not to Decide” Option for Older Adults Facing Dialysis Decisions
Show more Up Front Matters

Editorials

  • A Novel Pathological Mechanism of Tertiary Lymphoid Structure Formation in the Renal Pelvis
  • Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
  • Genome-wide Admixture Mapping of eGFR and CKD Identify European and African Ancestry-of-Origin Loci in US Hispanics/Latinos
Show more Editorials

Cited By...

  • Authors' Reply
  • Google Scholar

Similar Articles

Related Articles

  • Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy
  • PubMed
  • Google Scholar

Keywords

  • renal osteodystrophy
  • Bone Turnover
  • hyperparathyroidism

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire